Effect of Alendronate Administration on Bone Mineral Density and Bone Strength in Castrated Rats

Abstract

Castration of male rats leads to increased bone turnover and osteopenia. This study was conducted to examine the effects of the aminobisphosphonate alendronate on castration-induced bone changes. Bisphosphonates are drugs that inhibit bone turnover by decreasing the resorption. Since they suppress bone remodeling, they may also prevent the repair of microdamage and decrease bone strength. Although the mechanical properties of bones are directly related to the determination of fracture risk, bisphosphonate effects on the related variables have scarcely been investigated. Twenty-four male Wistar rats at two months of age were castrated or sham-operated to evaluate the effects of long-term administration (six months) of sodium alendronate at a dose of 1 mg/kg/day. The bones were tested mechanically by a three-point bending test in a Mini Bionix (MTS) testing system. High bone remodeling seen in castrated rats expressed by increased TrACP and B-ALP was suppressed by alendronate administration. Bone from castrated rats was characterized by a reduction in bone density as well as ash, calcium and phosphate content. Castration significantly altered mechanical properties of bone and femoral cortical thickness. When castrated rats were treated with high dose of alendronate, the changes in bone density resulting from castration were entirely prevented, and mechanical analysis revealed preserved mechanical strength of femur and cortical thickness. We conclude that castration induces cortical bone loss associated with high bone turnover in the male rat, and this bone loss can be prevented by alendronate through the inhibition of osteoclastic activity, while preserving the mechanical properties of bone. These results document the efficacy of alendronate, even at high doses, in preventing bone loss, loss of bone mechanical strength, and the rise in biochemical bone turnover indicators due to castration in rats, and raises the possibility that a alendronate could be equally effective in humans.

Key words

Castration - Alendronate - Bone density - Bone strength

References

• 1 Fleisch H. Bisphosphonates: Mechanismus of action.  Endocrine reviews. 1998;  19 80-100
• 2 Nevitt M G, Thompson D E, Black D M, Rubin S R, Eusund K, Yates A J, Cummings S R. Effect of alendronate on limited days and bed disability days caused by back pain in postmenopausal women with existing vertebral fractures.  Archives of Internal Medicine. 2000;  160 77-85
• 3 Mashiba T, Turner C H, Hirano T, Forwood M R, Johnston C C, Burr D B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles.  Bone. 2001;  28 524-531
• 4 Frost H M, Jee W SS. On the rat model of human osteopenias and osteoporoses.  Bone Miner. 1992;  18 227-1236
• 5 Mosekilde L. Assessing bone quality-animal models in preclinical osteoporosis research.  Bone. 1995;  17 3435-3525
• 6 Faulkner K G. Bone matters: are density increases necessary to reduce fracture risk?.  J Bone Miner res. 2000;  15 183-187
• 7 Kalu D N, Hardin R R, Ceckerham R. Evaluation of the pathogenesis of skeletal changes in ovariectomized rats.  Endocrinology. 1994;  115 507-511
• 8 Gitelman H. An improved automated procedure for the determination of calcium in biological specimens.  Anal Biochem. 1967;  18 521-531
• 9 Kraml J. A semiautomated determination of phospholipids.  Clin Chim Acta. 1966;  13 442-448
• 10 Štěpán J J, Šilinková-Málková E, Havránek T, Formánková J, Zichová J, Lachmanová J, Traková M, Broulik P, Pacovský V. Relationship of plasma tartrate-resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperpathyrodism.  Clin Chim Acta. 1983;  133 189-200
• 11 Moss D. A simplified heat-inactivation method for investigation alkaline phosphatase Isoenzymes in serum.  Clin Chim Acta. 1975;  61 63-71
• 12 Beall P T, Misra L K, Young R L, Spjut H J, Evans H J, Le Blame A. Clomiphene protects against osteoporosis in the mature ovariectomized rat.  Calcif Tissue Int. 1984;  36 123-125
• 13 Vanderschueren D E, Vautterck A MH, Suiker W J, Wisser L PC, Schot R, Bouillon R. Bone and mineral metabolism in aged male rats. Short and long term effects of androgen deficiency.  Endocrinology. 1992;  130 2906-2916
• 14 Turner C H, Burr D B. Basic biomechanical measurements of bone: A tutorial.  Bone. 1993;  14 595-608
• 15 Růžička R, Michálek J, Rosenkrancová J, Sedláček R. Cross section parameters acquisition from digital images. Prague: Proc. Of workshop 2002.  Prague CTU,. 2002;  B 910-911
• 16 Duncan D. Multiple range and multiple F test.  Biometrics. 1955;  11 1-4
• 17 Seeman E. Unresolved issues in osteoporosis in men.  Rev in Endocrine and Metabolic Disorders. 2001;  2 45-64
• 18 Orwoll E, Ettinger M, Weiss S. Alendronate for the treatment of osteoporosis in men.  N Engl J Med 2000; 343 : 604 - 610.. 1999;  14(suppl 1) S 184 Abstract 1205
• 19 Burr D B, Forwood M R, Fyhrie D P, Martin R B, Schaffer M B, Turner C HH. Bone microdemage and skeletal fragility in osteoporotic and stress fractures.  J Bone Miner Res. 1997;  12 6-15
• 20 Ott S M. Fractures after long term alendronate therapy.  J Clin Endocrinol Metab. 2001;  86 1835-1842
• 21 Laurutzen D B, Balena R, Shea M, Seedor J G, Markatos A, Le H M, Toolan B C, Myers E R, Rodan G A, Hayes W C. Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats.  J Bone Miner Res. 1993;  8 871-879
• 22 Azuma Y, Oue Y, Kanatani H, Ohta T, Kiyoki M, Komoriya K. Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats.  J Pharmacol Exp Ther. 1998;  286 128-135
• 23 Giavaresi G, Fini M, Gnudi S, Aldinin N N, Roca M, Carpi A, Giardino R. Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone.  Biomed Pharmacother. 2001;  55 397-403
• 24 Ito M, Azuma Y, Takagi H, Kamimura T, Komoriya K, Ohta T, Kawaguchi H. Preventive effects of sequential treatment with alendronate and in 1 alpha-hydroxyvitamin D3 on bone mass and strength in ovariectomized rats.  Bone. 2003;  33 90-99
• 25 Huuskonen J, Arnala I, Olkkonen H, Alhava E. Alendronate influences bending force of femoral diaphysis after orchidectomy in rats.  Ann Chir Gynaecol. 2001;  90 109-114
• 26 Wink C S, Felts W JL. Effects of castration on the bone structure of male rats. A model of osteoporosis.  Calcif Tissue Int. 1980;  32 77-82